Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02410733 | Evaluation of the Safety and Tolerability of i.v. Administration of a Cancer Vaccine in Patients With Advanced Melanoma(Lipo-MERIT) | completed | Phase 1 | 119 | BioNTech SEINDUSTRY | 1 | Mar 12, 2026 | clinicaltrials |
| NCT02858869 | Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases | completed | Phase 1 | 25 | Emory UniversityOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT01336270 | Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients(IMMUMELA) | completed | — | 217 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT07427953 | Clinical and Functional Retinal Changes Associated With BRAF/MEK Inhibitor Therapy in Patients With Malignant Melanoma | completed | — | 14 | Institute of Oncology LjubljanaOTHER | 1 | Mar 6, 2026 | clinicaltrials |
| NCT04335890 | IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma | completed | Phase 1 | 17 | Hasumi International Research FoundationOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07441538 | Optimizing the Timing for Facial Surgical Dressing Removal | completed | N/A | 144 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT07436390 | IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma(MAK) | completed | N/A | 132 | Institute of Oncology LjubljanaOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT01909453 | Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma(COLUMBUS) | completed | Phase 3 | 921 | PfizerINDUSTRY | 29 | Feb 27, 2026 | clinicaltrials |
| NCT03501368 | Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma | completed | Phase 1 | 27 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07434323 | Lavender Aromatherapy for Preoperative Anxiety in Melanoma and Epithelioma Patients(LAPAM) | completed | N/A | 66 | San Gallicano Dermatological Institute IRCCSOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT03400332 | A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers | completed | Phase 1 / Phase 2 | 281 | Bristol-Myers SquibbINDUSTRY | 12 | Feb 24, 2026 | clinicaltrials |
| NCT07428941 | Evaluating an Artificial Intelligence Tool to Help Primary Care Doctors Diagnose Skin Conditions.(LegitHealth PH) | completed | — | 9 | AI Labs Group S.LINDUSTRY | 1 | Feb 24, 2026 | clinicaltrials |
| NCT07428954 | Using Artificial Intelligence to Help Doctors Identify Different Skin Conditions and Improve Patient Care(LegitHealthSAN) | completed | — | 16 | AI Labs Group S.LINDUSTRY | 1 | Feb 24, 2026 | clinicaltrials |
| NCT07431489 | Retinal Structural and Functional Changes in Patients Treated With BRAF/MEK Inhibitors | completed | N/A | 30 | Institute of Oncology LjubljanaOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT01659151 | Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma | completed | Phase 2 | 17 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT02517736 | Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination(O-Mel-Sora) | completed | Phase 2 | 32 | University Hospital, CaenOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07411144 | Gemcitabine as Maintenance Treatment for Diffuse Pleural Mesothelioma(GEMO) | completed | Phase 2 | 64 | National Cancer Institute, EgyptOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT04552223 | Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma | completed | Phase 2 | 27 | Jose Lutzky, MDOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT03820986 | Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003) | completed | Phase 3 | 674 | Merck Sharp & Dohme LLCINDUSTRY | 18 | Feb 9, 2026 | clinicaltrials |
| NCT01625351 | A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas | completed | Phase 1 | 23 | St. Jude Children's Research HospitalOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT02910557 | Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection | completed | — | 187 | AmgenINDUSTRY | 5 | Feb 5, 2026 | clinicaltrials |
| NCT02989064 | MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers | completed | Phase 1 | 10 | AdaptimmuneINDUSTRY | 3 | Feb 4, 2026 | clinicaltrials |
| NCT03707574 | Genetic Analysis of Blood and Tissue Samples From Patients With Advanced Cancer, Moonshot Study | completed | — | 64 | National Cancer Institute (NCI)NIH | 2 | Feb 4, 2026 | clinicaltrials |
| NCT05419388 | A Study of Multiple Doses of RO7247669 in Participants With Previously Untreated Unresectable or Metastatic Melanoma | completed | Phase 2 | 93 | Hoffmann-La RocheINDUSTRY | 10 | Feb 4, 2026 | clinicaltrials |
| NCT07384299 | Impact of Skin Type on Wonud Healing and Scarring Following Facial Skin Surgery | completed | — | 173 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT03815058 | A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.(IMCODE001) | completed | Phase 2 | 131 | Genentech, Inc.INDUSTRY | 6 | Jan 30, 2026 | clinicaltrials |
| NCT01983748 | Dendritic Cells Plus Autologous Tumor RNA in Uveal Melanoma | completed | Phase 3 | 200 | University Hospital ErlangenOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03356470 | Pilot Study of Biomarkers of Response to Immune Checkpoint Blockade in Metastatic Melanoma | completed | — | 5 | University of Wisconsin, MadisonOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT00626860 | The Use of Dendritic Cell/Tumor Hybridomas as a Novel Tumor Vaccine in Patients With Advance Melanoma | completed | Phase 1 / Phase 2 | 20 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT02862743 | Molecular Characterization of Advanced Stage Melanoma by Blood Sampling(MELCIRC) | completed | N/A | 50 | CHU de ReimsOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT04109456 | IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma | completed | Phase 1 | 51 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 2 | Jan 15, 2026 | clinicaltrials |
| NCT03028948 | Interactive Tailored Website to Promote Sun Protection and Skin Self-Check Behaviors in Patients With Melanoma | completed | N/A | 485 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT02975700 | A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma | completed | N/A | 6 | Daiichi Sankyo Co., Ltd.INDUSTRY | 2 | Jan 13, 2026 | clinicaltrials |
| NCT04911998 | A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients(TavieSkin) | completed | — | 400 | Pierre Fabre MedicamentINDUSTRY | 1 | Jan 12, 2026 | clinicaltrials |
| NCT03873818 | Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain | completed | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT01004952 | Measuring Real Time Decision-Making About Ultraviolet Radiation (UVR) Protection | completed | — | 94 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT05707286 | Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy(ICI-PICK) | completed | — | 98 | Indiana UniversityOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT02917473 | Comparison of Two Strategies for Counseling Skin Examination and Sun Protection in First-degree Relatives of Patients With Melanoma(FADEMELA) | completed | N/A | 420 | University Hospital, ToursOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT04490564 | Validation of Molecular Diagnostic Assays to Detect Cancer Biomarkers in Blood and Primary Tumor in HNSCC/NSCLC/Melanoma | completed | — | 135 | Pharmassist LtdINDUSTRY | 1 | Dec 30, 2025 | clinicaltrials |
| NCT01970358 | A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma | completed | Phase 1 | 15 | Patrick Ott, MD, PhDOTHER | 1 | Dec 29, 2025 | clinicaltrials |
| NCT04889118 | Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study | completed | Phase 3 | 131 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT06120712 | A Study of GC101 TIL in Advanced Melanoma (BZ)(MIZAR-002) | completed | Phase 1 / Phase 2 | 18 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT01005745 | Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma | completed | N/A | 19 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT01701674 | Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts | completed | N/A | 13 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT03509467 | Using MC1R Genotype to Impact Melanoma Risk Behavior | completed | N/A | 2,054 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 2 | Dec 19, 2025 | clinicaltrials |
| NCT04082962 | Dexamethasone Implant for Retinal Detachment in Uveal Melanoma | completed | Phase 1 | 10 | Ivana K. KimOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT07256184 | Prognostic and Treatment-Response Factors in Metastatic Melanoma: Multi-Center Analysis(MEL-CARE) | completed | — | 232 | Ankara Etlik City HospitalOTHER_GOV | 1 | Dec 15, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Mar 12, 2026source: clinicaltrials